Cargando…

SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment

Adjuvant tamoxifen reduces the recurrence rate of estrogen receptor (ER)-positive breast cancer. Previous in vitro studies have suggested that tamoxifen can affect the cancerous inhibitor of protein phosphatase 2A (CIP2A)/protein phosphatase 2A (PP2A)/phosphorylation Akt (pAkt) signaling in ER-negat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Yu-Hsiang, Chu, Pei-Yi, Chen, Ji-Lin, Huang, Chun-Teng, Lee, Chia-Han, Lau, Ka-Yi, Wang, Wan-Lun, Wang, Yu-Ling, Lien, Pei-Ju, Tseng, Ling-Ming, Liu, Chun-Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162815/ https://www.ncbi.nlm.nih.gov/pubmed/30154367 http://dx.doi.org/10.3390/jcm7090245

Ejemplares similares

Expression pattern and prognostic impact of glycoprotein non-metastatic B (GPNMB) in triple-negative breast cancer
por: Huang, Yu-Hsiang, et al.
Publicado: (2021)

Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A–dependent phospho-Akt inactivation in estrogen receptor–negative human breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2014)

Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression
por: Liu, Chun-Yu, et al.
Publicado: (2019)

Sorafenib analogue SC‐60 induces apoptosis through the SHP‐1/STAT3 pathway and enhances docetaxel cytotoxicity in triple‐negative breast cancer cells
por: Liu, Chun‐Yu, et al.
Publicado: (2017)

The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2017)

Varlitinib Downregulates HER/ERK Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells
por: Liu, Chun-Yu, et al.
Publicado: (2019)

Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression
por: Huang, Tzu-Ting, et al.
Publicado: (2020)

Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2017)

PTEN promoter methylation predicts 10-year prognosis in hormone receptor-positive early breast cancer patients who received adjuvant tamoxifen endocrine therapy
por: Fan, Yu, et al.
Publicado: (2022)

Overexpression of Transcobalamin 1 is an Independent Negative Prognosticator in Rectal Cancers Receiving Concurrent Chemoradiotherapy
por: Lee, Yi-Ying, et al.
Publicado: (2017)

Adjuvant tamoxifen for early breast cancer.
por: Smith, I.
Publicado: (1988)

Tamoxifen resistance and adjuvant hormone therapy
por: Howell, A
Publicado: (2005)

Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase Inhibitors
por: Chang, Shih-Chieh, et al.
Publicado: (2019)

Progestins and the endometrium in patients receiving tamoxifen
Publicado: (1999)

Emerging Role of MicroRNA-200 Family in Dentistry
por: Hsieh, Pei-Ling, et al.
Publicado: (2021)

Adjuvant tamoxifen for male breast cancer (MBC).
por: Ribeiro, G., et al.
Publicado: (1992)

Correction: Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2017)

Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2016)

Developing a Web-Based Shared Decision-Making Tool for Fertility Preservation Among Reproductive-Age Women With Breast Cancer: An Action Research Approach
por: Tseng, Ling-Ming, et al.
Publicado: (2021)

Nuclear overexpression of the overexpressed in lung cancer 1 predicts worse prognosis in gastric adenocarcinoma
por: Wang, Jue, et al.
Publicado: (2016)

VDR mRNA overexpression is associated with worse prognostic factors in papillary thyroid carcinoma
por: Choi, June Young, et al.
Publicado: (2017)

Periostin overexpression is associated with worse prognosis in nasopharyngeal carcinoma from endemic area: a cohort study
por: Wei, Yu-Ching, et al.
Publicado: (2018)

KIF20A is a Prognostic Marker for Female Patients with Estrogen Receptor-Positive Breast Cancer and Receiving Tamoxifen as Adjuvant Endocrine Therapy
por: Huang, Xuchen, et al.
Publicado: (2023)

Comparisons of histological features among primary oral squamous cell carcinomas before and after adjuvant chemotherapy and their lymph node metastatic cancer lesions after adjuvant chemotherapy
por: Cheng, Feng-Chou, et al.
Publicado: (2022)

Postoperative Reduction Quality May Be the Most Important Factor That Causes Worse Functional Outcomes in Open and Closed Pelvic Fractures
por: Lai, Chih-Yang, et al.
Publicado: (2022)

Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex
por: Lin, Yu-Ling, et al.
Publicado: (2016)

MiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy
por: Zhong, XiaoRong, et al.
Publicado: (2016)

A Potential Oncogenic Role for PFKFB3 Overexpression in Gastric Cancer Progression
por: Lei, Lan, et al.
Publicado: (2021)

Effects of naturalistic decision-making model-based oncofertility care education for nurses and patients with breast cancer: a cluster randomized controlled trial
por: Huang, Sheng-Miauh, et al.
Publicado: (2022)

Correction to: Postoperative Reduction Quality May Be the Most Important Factor That Causes Worse Functional Outcomes in Open and Closed Pelvic Fractures
por: Lai, Chih-Yang, et al.
Publicado: (2022)

A Follow-Up Report of an Infant Born to a Mother Receiving Tamoxifen
por: Okada, Yuki, et al.
Publicado: (2020)

Bone mineral content of women receiving tamoxifen for mastalgia.
por: Fentiman, I. S., et al.
Publicado: (1989)

Ovarian cysts in women receiving tamoxifen for breast cancer
por: Mourits, M J E, et al.
Publicado: (1999)

Hyperbaric Oxygen Therapy Adjuvant Chemotherapy and Radiotherapy through Inhibiting Stemness in Glioblastoma
por: Yuen, Chun-Man, et al.
Publicado: (2023)

Overexpression of LGR-5 as a Predictor of Poor Outcome in Patients with Hepatocellular Carcinoma
por: Ko, Chih-Jan, et al.
Publicado: (2019)

The Christie hospital adjuvant tamoxifen trial--status at 10 years.
por: Ribeiro, G., et al.
Publicado: (1988)

Adherence to Adjuvant Tamoxifen in Mexican Young Women with Breast Cancer
por: Martinez-Cannon, Bertha Alejandra, et al.
Publicado: (2021)

Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors
por: Uslu, Yasemin, et al.
Publicado: (2023)

Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen
por: Chen, I-Chun, et al.
Publicado: (2017)

MUC1 overexpression predicts worse survival in patients with non-small cell lung cancer: evidence from an updated meta-analysis
por: Huang, Xing, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n4djv5ceu5ridrehcjpr09jobk